Literature DB >> 16719881

Tramadol vs morphine during adenotonsillectomy for obstructive sleep apnea in children.

Bruce J Hullett1, Neil A Chambers, Elaine M Pascoe, Chris Johnson.   

Abstract

BACKGROUND: Optimal analgesia for children undergoing adenotonsillectomy for obstructive sleep apnea (OSA) is controversial. Tramadol may represent a superior choice over morphine in this group, with a potential to cause less postoperative sedation and respiratory depression. Optimal perioperative analgesia may allow expensive and time-consuming preoperative work-up and postoperative monitoring to be rationalized.
METHODS: Sixty-six children were randomized to receive either perioperative tramadol or morphine in this double blinded, prospective, controlled trial. Postoperative sedation, pain, respiratory events, and vomiting were then compared between groups.
RESULTS: There was no significant difference between the two groups in sedation scores 1 h after arrival in recovery (P = 0.24) or at any other time up to 6 h postoperation. There was also no evidence of a difference between the groups in pain scores up to 6 h postoperation. There were fewer episodes of postoperative desaturation (<94%) in the tramadol group up to 3 h postoperation, with 26% fewer episodes in the tramadol group during the second hour postoperation (P = 0.02). Overall, there was a trend toward fewer desaturation episodes in the tramadol group.
CONCLUSIONS: Tramadol may be a suitable drug for children undergoing adenotonsillectomy for OSA. Further work is required to investigate this.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719881     DOI: 10.1111/j.1460-9592.2005.01827.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  10 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 2.  Tramadol for postoperative pain treatment in children.

Authors:  Alexander Schnabel; Sylvia U Reichl; Christine Meyer-Frießem; Peter K Zahn; Esther Pogatzki-Zahn
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

Review 3.  Opioid use and the risk of respiratory depression and death in the pediatric population.

Authors:  Marianne R Whittaker
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

4.  Comparison of early postoperative pain among surgical techniques for obstructive sleep apnea.

Authors:  Timur Akcam; Hasan Huseyin Arslan; Suleyman Deniz; Hakan Genc; Omer Karakoc; Serkan Senkal; Mustafa Gerek
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-15       Impact factor: 2.503

5.  Obstructive sleep apnoea syndrome in children and anaesthesia.

Authors:  A Rudra; Manjushree Ray; S Sengupta; Asif Iqbal; G Maitra; S Chatterjee
Journal:  Indian J Anaesth       Date:  2010-01

6.  Obstructive Sleep Apnea and Surgery: Quality Improvement Imperatives and Opportunities.

Authors:  Michael J Brenner; Julie L Goldman
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-03-01

Review 7.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  The comparison of ketamine with tramadol for postoperative pain relief on children following adenotonsillectomy or tonsillectomy: A meta-analysis of randomized controlled trials.

Authors:  Lifeng Wang; Yongkang Guo; Jun Tian
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

9.  Comparison of the effects of dexmedetomidine-ketamine and sevoflurane-sufentanil anesthesia in children with obstructive sleep apnea after uvulopalatopharyngoplasty: An observational study.

Authors:  Xinqi Cheng; Yue Huang; Qing Zhao; Erwei Gu
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-01

10.  Doing without codeine: why and what are the alternatives?

Authors:  Franca Benini; Egidio Barbi
Journal:  Ital J Pediatr       Date:  2014-02-11       Impact factor: 2.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.